Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers

Jared T. Hinkle; Kate Perepezko; Catherine C. Bakker; Martijn P. G. Broen; Kathleen Chin; Ted M. Dawson; Vanessa Johnson; Zoltan Mari; Cherie L. Marvel; Kelly A. Mills; Alexander Pantelyat; Olga Pletnikova; Liana S. Rosenthal; Melissa D. Shepard; Daniel A. Stevens; Juan C. Troncoso; Jiangxia Wang; Gregory M. Pontone

doi:10.1002/mdc3.12550

Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers

Jared T. Hinkle, Kate Perepezko, Catherine C. Bakker, Martijn P. G. Broen, Kathleen Chin, Ted M. Dawson, Vanessa Johnson, Zoltan Mari, Cherie L. Marvel, Kelly A. Mills, Alexander Pantelyat, Olga Pletnikova, Liana S. Rosenthal, Melissa D. Shepard, Daniel A. Stevens, Juan C. Troncoso, Jiangxia Wang, Gregory M. Pontone^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Psychosis is among the most disabling complications of Parkinson's disease (PD). The chronicity of PD psychosis remains understudied, and the relative importance of dopaminergic therapy versus the disease process itself in engendering psychosis remains unclear. The objective of this study was to examine pharmacologic and motoric correlates of PD psychosis onset and remission in a longitudinally monitored PD cohort. Methods: We analyzed data from 165 participants enrolled in a longitudinal PD study through the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins University. Evaluations included formal psychiatric assessment and were conducted at 2-year intervals. Regression with generalized estimated equations was used to produce unadjusted and adjusted estimates for time-varying longitudinal associations between psychosis and putative risk factors. Results: Sixty-two participants (37.6%) were diagnosed with psychosis during at least 1 evaluation. Of 49 participants with psychosis who were followed over multiple evaluations, 13 (26.5%) demonstrated remission despite a significant increase in Hoehn & Yahr stage (P=0.009); 2 of these individuals later relapsed. Multivariable regression with generalized estimated equations identified dementia diagnosis, akinesia-rigidity, anticholinergic usage, and levodopa-carbidopa dose as significantly associated with psychosis, whereas disease duration was not. A subanalysis of 30 incident psychosis cases suggested that the dopamine agonist dose was lowered after psychosis onset with a compensatory increase in the levodopa-carbidopa dosage. Conclusion: The current findings suggest that, in the context of standard therapy, PD-related psychotic disorder can remit at a frequency of approximately 27%. In addition, akinetic-rigid motor impairment was more strongly associated with psychosis than disease duration, independent of cognitive impairment and medications.

Original language	English
Pages (from-to)	31-38
Number of pages	8
Journal	Movement Disorders Clinical Practice
Volume	5
Issue number	1
DOIs	https://doi.org/10.1002/mdc3.12550
Publication status	Published - 1 Jan 2018

Keywords

hallucinations
motor subtypes
Parkinson's disease
psychosis
remission
VISUAL HALLUCINATIONS
ALZHEIMERS-DISEASE
SUBTYPES
DELUSIONS
DIAGNOSIS
DEMENTIA

Access to Document

10.1002/mdc3.12550

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945218Licence: Other

Cite this

Hinkle, J. T., Perepezko, K., Bakker, C. C., Broen, M. P. G., Chin, K., Dawson, T. M., Johnson, V., Mari, Z., Marvel, C. L., Mills, K. A., Pantelyat, A., Pletnikova, O., Rosenthal, L. S., Shepard, M. D., Stevens, D. A., Troncoso, J. C., Wang, J., & Pontone, G. M. (2018). Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 5(1), 31-38. https://doi.org/10.1002/mdc3.12550

@article{afec2c417d554e20aedd34bce720145e,

title = "Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers",

abstract = "Background: Psychosis is among the most disabling complications of Parkinson's disease (PD). The chronicity of PD psychosis remains understudied, and the relative importance of dopaminergic therapy versus the disease process itself in engendering psychosis remains unclear. The objective of this study was to examine pharmacologic and motoric correlates of PD psychosis onset and remission in a longitudinally monitored PD cohort. Methods: We analyzed data from 165 participants enrolled in a longitudinal PD study through the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins University. Evaluations included formal psychiatric assessment and were conducted at 2-year intervals. Regression with generalized estimated equations was used to produce unadjusted and adjusted estimates for time-varying longitudinal associations between psychosis and putative risk factors. Results: Sixty-two participants (37.6\%) were diagnosed with psychosis during at least 1 evaluation. Of 49 participants with psychosis who were followed over multiple evaluations, 13 (26.5\%) demonstrated remission despite a significant increase in Hoehn \& Yahr stage (P=0.009); 2 of these individuals later relapsed. Multivariable regression with generalized estimated equations identified dementia diagnosis, akinesia-rigidity, anticholinergic usage, and levodopa-carbidopa dose as significantly associated with psychosis, whereas disease duration was not. A subanalysis of 30 incident psychosis cases suggested that the dopamine agonist dose was lowered after psychosis onset with a compensatory increase in the levodopa-carbidopa dosage. Conclusion: The current findings suggest that, in the context of standard therapy, PD-related psychotic disorder can remit at a frequency of approximately 27\%. In addition, akinetic-rigid motor impairment was more strongly associated with psychosis than disease duration, independent of cognitive impairment and medications.",

keywords = "hallucinations, motor subtypes, Parkinson's disease, psychosis, remission, VISUAL HALLUCINATIONS, ALZHEIMERS-DISEASE, SUBTYPES, DELUSIONS, DIAGNOSIS, DEMENTIA",

author = "Hinkle, \{Jared T.\} and Kate Perepezko and Bakker, \{Catherine C.\} and Broen, \{Martijn P. G.\} and Kathleen Chin and Dawson, \{Ted M.\} and Vanessa Johnson and Zoltan Mari and Marvel, \{Cherie L.\} and Mills, \{Kelly A.\} and Alexander Pantelyat and Olga Pletnikova and Rosenthal, \{Liana S.\} and Shepard, \{Melissa D.\} and Stevens, \{Daniel A.\} and Troncoso, \{Juan C.\} and Jiangxia Wang and Pontone, \{Gregory M.\}",

year = "2018",

month = jan,

day = "1",

doi = "10.1002/mdc3.12550",

language = "English",

volume = "5",

pages = "31--38",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "Wiley",

number = "1",

}

Hinkle, JT, Perepezko, K, Bakker, CC, Broen, MPG, Chin, K, Dawson, TM, Johnson, V, Mari, Z, Marvel, CL, Mills, KA, Pantelyat, A, Pletnikova, O, Rosenthal, LS, Shepard, MD, Stevens, DA, Troncoso, JC, Wang, J & Pontone, GM 2018, 'Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers', Movement Disorders Clinical Practice, vol. 5, no. 1, pp. 31-38. https://doi.org/10.1002/mdc3.12550

TY - JOUR

T1 - Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers

AU - Hinkle, Jared T.

AU - Perepezko, Kate

AU - Bakker, Catherine C.

AU - Broen, Martijn P. G.

AU - Chin, Kathleen

AU - Dawson, Ted M.

AU - Johnson, Vanessa

AU - Mari, Zoltan

AU - Marvel, Cherie L.

AU - Mills, Kelly A.

AU - Pantelyat, Alexander

AU - Pletnikova, Olga

AU - Rosenthal, Liana S.

AU - Shepard, Melissa D.

AU - Stevens, Daniel A.

AU - Troncoso, Juan C.

AU - Wang, Jiangxia

AU - Pontone, Gregory M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Psychosis is among the most disabling complications of Parkinson's disease (PD). The chronicity of PD psychosis remains understudied, and the relative importance of dopaminergic therapy versus the disease process itself in engendering psychosis remains unclear. The objective of this study was to examine pharmacologic and motoric correlates of PD psychosis onset and remission in a longitudinally monitored PD cohort. Methods: We analyzed data from 165 participants enrolled in a longitudinal PD study through the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins University. Evaluations included formal psychiatric assessment and were conducted at 2-year intervals. Regression with generalized estimated equations was used to produce unadjusted and adjusted estimates for time-varying longitudinal associations between psychosis and putative risk factors. Results: Sixty-two participants (37.6%) were diagnosed with psychosis during at least 1 evaluation. Of 49 participants with psychosis who were followed over multiple evaluations, 13 (26.5%) demonstrated remission despite a significant increase in Hoehn & Yahr stage (P=0.009); 2 of these individuals later relapsed. Multivariable regression with generalized estimated equations identified dementia diagnosis, akinesia-rigidity, anticholinergic usage, and levodopa-carbidopa dose as significantly associated with psychosis, whereas disease duration was not. A subanalysis of 30 incident psychosis cases suggested that the dopamine agonist dose was lowered after psychosis onset with a compensatory increase in the levodopa-carbidopa dosage. Conclusion: The current findings suggest that, in the context of standard therapy, PD-related psychotic disorder can remit at a frequency of approximately 27%. In addition, akinetic-rigid motor impairment was more strongly associated with psychosis than disease duration, independent of cognitive impairment and medications.

AB - Background: Psychosis is among the most disabling complications of Parkinson's disease (PD). The chronicity of PD psychosis remains understudied, and the relative importance of dopaminergic therapy versus the disease process itself in engendering psychosis remains unclear. The objective of this study was to examine pharmacologic and motoric correlates of PD psychosis onset and remission in a longitudinally monitored PD cohort. Methods: We analyzed data from 165 participants enrolled in a longitudinal PD study through the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins University. Evaluations included formal psychiatric assessment and were conducted at 2-year intervals. Regression with generalized estimated equations was used to produce unadjusted and adjusted estimates for time-varying longitudinal associations between psychosis and putative risk factors. Results: Sixty-two participants (37.6%) were diagnosed with psychosis during at least 1 evaluation. Of 49 participants with psychosis who were followed over multiple evaluations, 13 (26.5%) demonstrated remission despite a significant increase in Hoehn & Yahr stage (P=0.009); 2 of these individuals later relapsed. Multivariable regression with generalized estimated equations identified dementia diagnosis, akinesia-rigidity, anticholinergic usage, and levodopa-carbidopa dose as significantly associated with psychosis, whereas disease duration was not. A subanalysis of 30 incident psychosis cases suggested that the dopamine agonist dose was lowered after psychosis onset with a compensatory increase in the levodopa-carbidopa dosage. Conclusion: The current findings suggest that, in the context of standard therapy, PD-related psychotic disorder can remit at a frequency of approximately 27%. In addition, akinetic-rigid motor impairment was more strongly associated with psychosis than disease duration, independent of cognitive impairment and medications.

KW - hallucinations

KW - motor subtypes

KW - Parkinson's disease

KW - psychosis

KW - remission

KW - VISUAL HALLUCINATIONS

KW - ALZHEIMERS-DISEASE

KW - SUBTYPES

KW - DELUSIONS

KW - DIAGNOSIS

KW - DEMENTIA

U2 - 10.1002/mdc3.12550

DO - 10.1002/mdc3.12550

M3 - Article

C2 - 29756003

SN - 2330-1619

VL - 5

SP - 31

EP - 38

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 1

ER -

Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers

Abstract

Keywords

Access to Document

Fingerprint

Cite this